Payment overview · 2025
General Payments
$617.54
11 reported records · 8 companies
Healthcare provider profile · identity verified
Cassandra Hawkins, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOLLY SPRINGS, MS · NPI 1982609004
Verified facts
What the public records show
CMS Open Payments records show Cassandra Hawkins, MD received $617.54 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.76 | 19.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $114.97 | 18.6% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $109.09 | 17.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.11 | 16.4% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $92.59 | 15.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.00 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.32 | 5.1% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $16.70 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.54 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $114.97 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $109.09 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $92.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.32 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 604 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 116 |
| Gabapentin | Gabapentin | 395 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 62 |
| Omeprazole | Omeprazole | 250 | 69 |
| Meloxicam | Meloxicam | 249 | 73 |
| Metformin Hcl | Metformin Hcl | 248 | 67 |
| Furosemide | Furosemide | 246 | 56 |
| Alprazolam | Alprazolam | 229 | 26 |
| Losartan Potassium | Losartan Potassium | 210 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 55 |
| Lisinopril | Lisinopril | 200 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 179 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 46 |
| Carvedilol | Carvedilol | 157 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 49 |
| Potassium Chloride | Potassium Chloride | 155 | 36 |
| Famotidine | Famotidine | 154 | 41 |
| Tramadol Hcl | Tramadol Hcl | 147 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 34 |
| Trazodone Hcl | Trazodone Hcl | 142 | 30 |
| Montelukast Sodium | Montelukast Sodium | 128 | 41 |
| Simvastatin | Simvastatin | 126 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 23 |
| Allopurinol | Allopurinol | 105 | 21 |
| Lovastatin | Lovastatin | 103 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 21 |
| Clonidine Hcl | Clonidine Hcl | 93 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 33 |
| Atenolol | Atenolol | 85 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 29 |
| Clonazepam | Clonazepam | 82 | 11 |
| Mounjaro | Tirzepatide | 82 | 13 |
| Farxiga | Dapagliflozin Propanediol | 77 | 21 |
| Donepezil Hcl | Donepezil Hcl | 74 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 17 |
| Glimepiride | Glimepiride | 72 | 20 |
| Trulicity | Dulaglutide | 72 | 18 |
| Levetiracetam | Levetiracetam | 70 | suppressed |
| Mirtazapine | Mirtazapine | 70 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Azithromycin | Azithromycin | 62 | 49 |
| Ozempic | Semaglutide | 60 | 12 |
| Topiramate | Topiramate | 59 | 13 |
| Glipizide | Glipizide | 57 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 13 |
| Lansoprazole | Lansoprazole | 56 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 24 |
| Methimazole | Methimazole | 53 | 11 |
| Methylprednisolone | Methylprednisolone | 51 | 37 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 15 |
| Jardiance | Empagliflozin | 49 | 14 |
| Colchicine | Colchicine | 48 | 11 |
| Linzess | Linaclotide | 47 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Fenofibrate | Fenofibrate | 44 | 11 |
| Eliquis | Apixaban | 43 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 14 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 15 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Naproxen | Naproxen | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Diazepam | Diazepam | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 13 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | 14 |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 13 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Prednisone | Prednisone | 22 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.54 · 11 records | Novo Nordisk Inc | DIAMONDBACK PERIPHERAL, Miro3D, Ozempic, Penumbra System, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error